These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19255904)

  • 1. Paradoxical echinocandin activity: a limited in vitro phenomenon?
    Wiederhold NP
    Med Mycol; 2009; 47 Suppl 1():S369-75. PubMed ID: 19255904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect.
    Wiederhold NP
    Curr Opin Infect Dis; 2007 Dec; 20(6):574-8. PubMed ID: 17975406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Eagle-like effect of echinocandins: what's in a name?
    Vanstraelen K; Lagrou K; Maertens J; Wauters J; Willems L; Spriet I
    Expert Rev Anti Infect Ther; 2013 Nov; 11(11):1179-91. PubMed ID: 24134556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
    Beyda ND; Lewis RE; Garey KW
    Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echinocandin pharmacodynamics: review and clinical implications.
    Pound MW; Townsend ML; Drew RH
    J Antimicrob Chemother; 2010 Jun; 65(6):1108-18. PubMed ID: 20335190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of serum on in vitro susceptibility testing of echinocandins for Candida parapsilosis and Candida guilliermondii.
    Saribas Z; Yurdakul P; Cetin-Hazirolan G; Arikan-Akdagli S
    Mycoses; 2012 Mar; 55(2):156-60. PubMed ID: 21668525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Echinocandin activity against Aspergillus spp. and the importance of pharmacodynamics.
    Lewis JS
    Med Mycol; 2009; 47 Suppl 1():S376-81. PubMed ID: 19296368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species.
    Zeidler U; Bougnoux ME; Lupan A; Helynck O; Doyen A; Garcia Z; Sertour N; Clavaud C; Munier-Lehmann H; Saveanu C; d'Enfert C
    J Antimicrob Chemother; 2013 Jun; 68(6):1285-96. PubMed ID: 23378416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition.
    Morikawa H; Tomishima M; Kayakiri N; Araki T; Barrett D; Akamatsu S; Matsumoto S; Uchida S; Nakai T; Takeda S; Maki K
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1172-5. PubMed ID: 24468413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
    Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
    Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential Microbiological Effects of Higher Dosing of Echinocandins.
    Steinbach WJ; Lamoth F; Juvvadi PR
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S669-77. PubMed ID: 26567286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echinocandin resistance in human pathogenic fungi.
    Munro CA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):115-6. PubMed ID: 22339184
    [No Abstract]   [Full Text] [Related]  

  • 15. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The echinocandins: three useful choices or three too many?
    Bal AM
    Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micafungin: a new echinocandin.
    Chandrasekar PH; Sobel JD
    Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
    Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
    J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.
    Chamilos G; Lewis RE; Albert N; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2257-9. PubMed ID: 17438060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.